Article

Quantel’s SLT glaucoma laser granted FDA clearance

Quantel Medical’s selective laser trabeculoplasty (SLT) glaucoma laser has been approved by the FDA.

Clermont-Ferrand, France-Quantel Medical’s selective laser trabeculoplasty (SLT) glaucoma laser has been approved by the FDA.

The laser, called Solutis, offers several features, which enable it to be integrated into a hospital or clinical setting.

The laser was designed to be adaptable to a physician’s current slit lamp, which then eliminates the need for dedicated space and lowers end-user cost.

The FDA’s clearance of the laser follows the expiration of a patent issued to Massachusetts General Hospital, which restricted Quantel and several other laser manufactures from marking SLT within the United States.

Quantel has been providing SLT technology outside the United States since 2007.

“This FDA market clearance of our SLT laser marks an important step in Quantel’s strategy for the U.S. market,” said Jean-Marc Gendre, chief executive officer of Quantel. “(The laser) has proven to be an attractive laser solution worldwide.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.